Skip to main content

Table 1 Demographics and baseline characteristics of the participants

From: The effect of methylphenidate on neurofibromatosis type 1: a randomised, double-blind, placebo-controlled, crossover trial

 

MPD/Placebo

Placebo/MPD

(n = 20)

(n = 19)

Age (y)

  

Mean*

9.60 +/-2.02

8.98 +/-1.63

Range

7.09-12.99

7.21-11.81

Gender

  

Male

16 (80.0%)

13 (68.4%)

Female

4 (20.0%)

6 (31.6%)

Weight (kg)*

29.34 (5.91)

29.04 (6.14)

Height (cm)*

132.50 (10.09)

133.63 (9.15)**

School backwardness

6 (30.0%)

7 (36.8%)

IQ*

102.0 (12.5)

94.6 (11.2)

Conners’ global index-Parents*

66.2 (13.9)

69.8 (16.1)

Conners’ global index-Teacher*

55.9 (8.4)¥

59.8 (9.0) ¥

Conners’ global index-Short version-Parents*

15.2 (5.2)

13.7 (6.4)

Conners’ global index-Short version-Teacher*

8.1 (4.7)¤

11.9 (6.1)**

CDRS-R*

29.9 (7.8)

27.6 (7.4)

CDI*

11.0 (6.5)

10.0 (4.6)

STAI-C 1*

12.9 (7.4)

10.9 (6.5)

STAI-C 2*

15.9 (9.1)

13.3 (7.5)

DSM IV THADA [28]

  

Inattention*

6.8 (1.5)

6.9 (2.0)

Hyperactivity/Impulsivity*

5.3 (2.0)

5.8 (3.0)

Hyperactivity*

3.0 (1.6)

3.9 (2.1)

Impulsivity*

2.3 (0.7)

1.9 (1.2)

  1. *Mean +/- SD.
  2. According to the difference between the child age and the expected age for the school level.
  3. **3 missing values.
  4. 1 missing value.
  5. 2 missing values.
  6. ¥4 missing values.
  7. ¤5 missing values.